EUROPEAN COMMISSION

Brussels, 5.10.2026
C(2026) 7128 final

PUBLIC VERSION

Accenture S.p.A.
Via Privata Nino Bonnet 10
20154 Milan
Italy

Subject: **Case M.12528 – ACCENTURE / INDX / ALFAHEALTH**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]) and Article 57 of the Agreement on the European Economic Area ([2])

Dear Sir or Madam,

(1) On 9 September 2026, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation, by which Accenture S.p.A. ('Accenture', Italy), ultimately controlled by Accenture plc (Ireland), will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the whole of Industries Excellence S.p.A. (Italy) and IT-SOFT USA, Inc. (United States) (together, 'IndX') and Alfahealth S.p.A. ('Alfahealth', Italy) by way of purchase of shares. ([3])

(2) The business activities of the undertakings concerned are the following:

– Accenture is a global provider of IT services,

– IndX is a global provider of IT services and IT software for industrial sectors,

– Alfahealth is a provider of IT software and IT services for the healthcare sector in Italy.

(3) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.
([2]) OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
([3]) OJ C, C/2026/4896, 17.9.2026.

paragraph 5(d) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ([4])

(4) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Anthony WHELAN
Director-General
Directorate-General for Competition

([4]) OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment').